| | |
Group
|
P
|
|---|
|
Transplant Pts
|
Non-transplant Pts
|
Total
|
|---|
|
Count (N %)
|
Count (N %)
|
Count (N %)
|
|---|
|
Age group
|
Low—50 yrs
|
11 (45.8)
|
16 (40.0)
|
27 (42.2)
|
0.491
|
| |
50—59 yrs
|
4 (16.7)
|
12 (30.0)
|
16 (25.0)
| |
| |
60—high yrs
|
9 (37.5)
|
12 (30.0)
|
21 (32.8)
| |
|
Age
|
52.25 ± 12.88 (29.00 – 76.00)
|
51.58 ± 11.32 (32.0 – 72.0)
|
51.83 ± 11.83 (29.0 – 76.0)
| | |
|
Sex
|
Male
|
17 (70.8)
|
24 (60.0)
|
41 (64.1)
|
0.431
|
| |
Female
|
7 (29.2)
|
16 (40.0)
|
23 (35.9)
| |
|
HTN
| |
20 (87.0)
|
16 (41.0)
|
36 (58.1)
|
< 0.001
|
|
Diabetes
| |
11 (47.8)
|
12 (30.8)
|
23 (37.1)
|
0.179
|
|
CVA
| |
1 (4.3)
|
1 (2.6)
|
2 (3.2)
|
0.608
|
|
IHD or HF
| |
4 (17.4)
|
8 (20.5)
|
12 (19.4)
|
0.520
|
|
DVT
| |
1 (4.3)
|
0 (0.0)
|
1 (1.6)
|
0.371
|
|
PTE
| |
0 (0.0)
|
1 (2.6)
|
1 (1.6)
|
0.621
|
|
COPD
| |
1 (4.3)
|
7 (17.9)
|
8 (12.9)
|
0.123
|
|
Cellcept
| |
24 (12.9)
| |
24 (100.0)
|
-
|
|
Cyclosporine
| |
13 (56.5)
| |
13 (56.5)
| |
|
Tacrolimus
| |
9 (40.9)
| |
9 (40.9)
| |
|
Sirolimus
| |
1 (4.3)
| |
1 (4.3)
| |
|
Corticosteroid
| |
23 (95.8)
|
4 (10.0)
|
27 (42.2)
|
0.001
|
|
ARB or ACEi
| |
6 (25.0)
|
13 (34.2)
|
22 (36.7)
|
0.444
|
|
Atorvastatin
| |
20 (83.3)
|
13 (34.2)
|
31 (50.8)
|
0.001
|
|
Warfarin
| |
1
(4.3)
|
2 (5.3)
|
3 (4.9)
|
0.684
|
|
HCQ
| |
23 (95.8)
|
40 (100.0)
|
63 (98.4)
|
0.375
|
|
Kaletra
| |
17 (70.8)
|
30 (75.0)
|
47 (73.4)
|
0.715
|
|
Tamiflu
| |
16 (66.7)
|
21 (52.5)
|
37 (57.8)
|
0.267
|
|
Azithromycin
| |
2 (8.3)
|
8 (20.0)
|
10 (15.6)
|
0.189
|
|
IVIG
| |
4 (16.7)
|
0 (0.0)
|
4 (6.3)
|
0.017
|
|
Gancyclovir
| |
1 (4.2)
|
0 (0.0)
|
1 (1.6)
|
0.375
|
|
Ribavirin
| |
2 (8.3)
|
0 (0.0)
|
2 (3.1)
|
0.137
|
